Antiangiogenic treatment as a pre‐operative management of alveolar soft‐part sarcoma

Alveolar soft-part sarcoma (ASPS) is a rare tumor. Cure is based solely on radical surgery. The general prognosis is poor. The tongue is an unusual site in adults, but not in children. Tumor removal can cause a severe impact on quality of life, even if reconstruction is possible. ASPS is a highly vascularized tumor and antiangiogenic therapy may have a role. We describe the use of the antiangiogenic combination bevacizumab and celecoxib in the preoperative management of a patient with an ASPS of the tongue. Pediatr Blood Cancer 2011; 57: 1071–1073. © 2011 Wiley-Liss, Inc.